1Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia[ J]. Senlin Oncol,2002,29 (5 Suppl 14) :3-9.
2Denning MF ,Dlugosz AA, Cbeng C, et al. Cross-talk between epidermal growth factor receptor and protein kinase C during calcium-induced differentiation of keratinocytes [ J ]. Exp Dermatol, 2000,9 (3):192-199.
3The epidermal growth factor receptor in lung cancer [ J ]. Sign, 2001,2 (1) :13.
4CiardieUo F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer ceils by ZD1839 ( Iressa), an epidermal growth factor receptor selective tyrosine kinase inhibitor[ J]. Clin Cancer Res,2000,6(5) :2053-2063.
5Fukuoka M,Yano S, Giaccone G,et al. Multi-institution a randomized phase Ⅱ trial of gefinitib for previously treated patients with advanced non-small-ceU lung cancer [ J ]. J Clin Oncol, 2003,21(12): 2237.
6Kris MG,Natale RB ,Herbst RS,et al. Efficacy of gefitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer: a randomized trial[J]. JAMA,2003,290 ( 16 ) :2149-2158.
7Twombly R. Failing survival advantage in crucial trial, future of Iressa is in jeopardy [ J ]. J Natl Cancer Inst, 2005,97 (4) :249- 250.
8Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase Ⅲ trial( INTACT1 ) [ J ]. J Clin Oncol,2004, 22(5): 777.
9Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase Ⅲ trial ( INTACT 2 ) [ J ]. J Clin Oncol, 2004,22 (5) :785-794.
10Risehin D, Burmeister B, Mitchell, et al. Phase I trial of gefitinib (ZD1839) in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage Ⅲ non-small-cell lung cancer[ J ]. Proc Am Soc Clin Oncol,2004,23: 632 ( Abs7077 ).
